‘Powerlifting granny' inspires with vibrant, healthy lifestyle
CHICAGO — Ginger Mance is a Chicago area 74-year-old known as the 'powerlifting granny.'
Two words that are not in her vocabulary? 'Granny' and 'old.'
In fact, you'd be hard pressed to find anyone as vibrant, strong and motivated as Mance. She is in a league all her own.
Some thought her listed age was a typo when she joined the rooster at last month's Windy City Classic.
'I'm probably shocked that they're shocked that I'm 74, because I feel like this is how 74 should look!' she said.
More info on Ginger on her
She walked away with atrophy as she set another state and national record for her age group.
She also teaches about health at her local Y and has authored some poetry books.
'If you plant in your mind that 'I'm old at 60' and 'I'm old at 70,' then yes, you will be old, using a cane and a walker,' she said. 'I post my lifts not to brag about what I'm doing, but to show you what you can do.'
Lifting others is her biggest win of all.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
31 minutes ago
- Business Wire
Guided Therapeutics Receives $700,000 Purchase Order and Initial Payment from New Chinese Distributor
PEACHTREE CORNERS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, announced today that it had received a purchase order and first payment from Hangzhou Dongye Medical Technology Company Ltd (HDMT) for 35 LuViva systems. HDMT will order directly from Guided Therapeutics and the devices will be assembled and tested by Guided Therapeutics' Chinese partner, Shandong Yaohua Medical Instrument Corporation (SMI). HDMT is in Hangzhou City, Zhejiang Province, where it is the exclusive gynecology products provider for 42 hospitals that perform approximately two million cervical cancer screenings annually. Said Yang Dongye, CEO of HDMT: 'We are extremely impressed with the performance of LuViva and our goal is to eventually replace the current screening tests with LuViva.' The purchase order for $700,000 is to supply HDMT with 35 systems over the next eight months starting in July of this year. 'We are extremely pleased to be working with HDMT to bring LuViva to Zhejiang Province and anticipate making initial shipments next month,' added Mark Faupel, Guided Therapeutics' CEO. 'Working directly with an exclusive provider of gynecology products that can potentially conduct two million LuViva tests each year is a major advance for GTI.' About Guided Therapeutics Guided Therapeutics, Inc. (OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company's first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. For more information, visit: The Guided Therapeutics LuViva ® Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use in the U.S. LuViva, the wave logo and "Early detection, better outcomes" are registered trademarks owned by Guided Therapeutics, Inc. Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics' actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to the early stage of commercialization of products, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the sufficiency of capital raised in prior financings and the ability to realize their expected benefits, the uncertainty of future capital to develop products or continue as a going concern, the uncertainty of regulatory approval of products, and the dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading 'Risk Factors' in Guided Therapeutics' reports filed with the SEC, including Guided Therapeutics' Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and subsequent filings.
Business Wire
an hour ago
- Business Wire
Tandem Diabetes Care Announces Agreement with Abbott for Integration of Automated Insulin Delivery Systems with Future Glucose-Ketone Sensor
SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced an agreement to develop and commercialize integrated diabetes solutions that combine Abbott's future dual glucose-ketone sensor with Tandem's innovative insulin delivery systems to provide more options for people to manage their diabetes. The Abbott sensor, currently under development, will combine glucose and ketone sensing technology that aims to help people living with diabetes detect early ketone rise to avoid life-threatening diabetic ketoacidosis. "Integrating our advanced insulin delivery systems with Abbott's future glucose-ketone sensor has the potential to help empower people with diabetes to take faster, more informed action to protect their health and improve outcomes," said John Sheridan, president and chief executive officer. "We are excited to continue our partnership with Abbott and look forward to working with them to bring this new integration to customers in the future." About Tandem Diabetes Care, Inc. Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company's pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ+ advanced hybrid closed-loop technology. Tandem Diabetes Care is based in San Diego, California. For more information, visit Follow @TandemDiabetes on Facebook, Instagram, LinkedIn, TikTok, and X. Forward-looking Statements This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements relate to, among other things, development plans to integrate Tandem insulin delivery systems with Abbott dual glucose and ketone sensing technology. These forward-looking statements are subject to numerous risks and uncertainties, including risks, for example, that technical challenges, clinical or regulatory hurdles or other factors may prevent or delay integration, as well as other risks identified in our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other documents that we file with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Actual results could differ materially from those anticipated or projected in the forward-looking statements. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events or other factors. ©2025 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, the Tandem logo, Control-IQ+, Tandem Mobi and t:slim X2 are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries. All third-party marks are the property of their respective owners.
Business Wire
2 hours ago
- Business Wire
Prevencio Awarded U.S., European and Japanese Patents for HART CADhs, Its AI-Driven Blood Test for Coronary Artery Disease
KIRKLAND, Wash.--(BUSINESS WIRE)-- Prevencio, Inc., the leader in artificial intelligence-powered blood tests for cardiovascular disease, today announced that it has been granted patents for its HART CADhs® test in the United States—marking the second U.S. patent for this novel test—as well as the European Union and Japan. These patents protect Prevencio's proprietary methods and algorithms for detecting obstructive coronary artery disease (CAD) using a multi-protein, AI-driven blood test platform. The newly issued patents strengthen Prevencio's intellectual property portfolio and support its long-term strategy to expand HART CADhs adoption globally. HART CADhs is the only blood test that combines multiple cardiac proteins with machine learning to deliver a highly accurate, non-invasive diagnosis of obstructive CAD. 'Securing patent protection in the U.S., Europe, and Japan marks a major step forward in advancing our innovation and market leadership,' said Rhonda Rhyne, Chief Executive Officer of Prevencio. 'These patents reinforce the uniqueness of our HART CADhs test and underscore our commitment to improving cardiovascular diagnostics worldwide.' Prevencio is redefining the future of cardiovascular diagnostics. With two marketed, AI-driven blood tests—HART CADhs and HART CVE—and bolstered by international patent protection, compelling clinical data, reimbursement, and recent FDA Breakthrough Device Designation, Prevencio uniquely delivers a convergence of innovation, validation, and commercial readiness. 'Cardiovascular disease is a global problem. International patent protection will help Prevencio to deliver scalable solutions that meet urgent diagnostic needs in the U.S. as well as global markets,' said James L. Januzzi, MD, a practicing cardiologist at MGH, Professor of Medicine at Harvard Medical School, Chief Scientific Officer at the Baim Institute for Clinical Research and Principal Investigator for the HART test development and validation. Cardiovascular disease remains the leading cause of death worldwide and accounts for more than $318 billion in annual U.S. healthcare costs, nearly 10% of total healthcare spending. Prevencio's HART blood tests are designed to improve accessibility, accuracy, and patient outcomes while reducing costs through earlier, more accessible, and accurate blood diagnostics. Both HART CADhs and HART CVE, a second AI-driven, multi-protein blood test that assesses a patient's one-year risk of heart attack, stroke, or cardiovascular death, are currently available to healthcare providers and for research use. About Prevencio, Inc. Prevencio is transforming cardiovascular care through AI-driven blood tests that deliver earlier, accurate, and more accessible diagnostics. The company's HART platform powers the development of proprietary tests for cardiovascular disease, including HART CADhs® for detecting obstructive coronary artery disease and HART CVE® for assessing one-year risk of heart attack, stroke, or cardiovascular death. For more information, visit Forward-Looking Statement: Except for historical and factual information contained herein, this press release contains forward-looking statements, the accuracy of which is subject to various uncertainties of early stage companies. The company does not undertake to update disclosures contained in this press release.
